SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors

Christine S. Higham, Seth M. Steinberg, Eva Dombi, Arie Perry, Lee J. Helman, Scott M. Schuetze, Joseph A. Ludwig, Arthur Staddon, Mohammed M. Milhem, Daniel Rushing, Robin L. Jones, Michael Livingston, Stewart Goldman, Christopher Moertel, Lars Wagner, David Janhofer, Christina M. Annunziata, Denise Reinke, Lauren Long, David ViskochilLarry Baker, Brigitte C. Widemann

Research output: Contribution to journalArticlepeer-review

45 Scopus citations


Background. Worse chemotherapy response for neurofibromatosis type 1- (NF1-) associated compared to sporadic malignant peripheral nerve sheath tumors (MPNST) has been reported. Methods. We evaluated the objective response (OR) rate of patients with AJCC Stage III/IV chemotherapy-naive NF1 MPNST versus sporadic MPNST after 4 cycles of neoadjuvant chemotherapy, 2 cycles of ifosfamide/doxorubicin, and 2 cycles of ifosfamide/etoposide. A Simon optimal two-stage design was used (target response rate 40%). Results. 34 NF1 (median age 33 years) and 14 sporadic (median age 40 years) MPNST patients enrolled. Five of 28 (17.9%) evaluable NF1 MPNST patients had a partial response (PR), as did 4 of 9 (44.4%) patients with sporadic MPNST. Stable disease (SD) was achieved in 22 NF1 and 4 sporadic MPNST patients. In both strata, results in the initial stages met criteria for expansion of enrollment. Only 1 additional PR was observed in the expanded NF1 stratum. Enrollment was slower than expected and the trial closed before full accrual. Conclusions. This trial was not powered to detect differences in response rates between NF1 and sporadic MPNST. While the OR rate was lower in NF1 compared to sporadic MPNST, qualitative responses were similar, and disease stabilization was achieved in most patients.

Original languageEnglish (US)
Article number8685638
StatePublished - 2017

Bibliographical note

Funding Information:
2.1. Study Oversight. This multi-institutional trial was sponsored by the United States Department of Defense (DoD), developed by NCI investigators in collaboration with the Sarcoma Alliance for Research through Collaboration (SARC) and coordinated by SARC. The protocol was approved by the local institutional review board at each participating site and registered on NCT00304083. All patients or their legal guardians provided written informed consent and assent (patients 13 through 17 years old).

Funding Information:
This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Department of Defense Neurofibromatosis Research Program under Award no. W81XWH-06-1-0434. This research was also supported, in part, through the NCI CCR Intramural Research Program.

Publisher Copyright:
© 2017 Christine S. Higham et al.


Dive into the research topics of 'SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors'. Together they form a unique fingerprint.

Cite this